Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016
Published Sep 14, 2016
172 pages — Published Sep 14, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016, provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
- The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects
- The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of l

  
Source:
Document ID
GMDHC8460IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables101
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Human Papillomavirus (HPV) Associated Cancer Overview131
Therapeutics Development142
  Pipeline Products for Human Papillomavirus (HPV) Associated Cancer Overview141
  Pipeline Products for Human Papillomavirus (HPV) Associated Cancer Comparative Analysis151
Human Papillomavirus (HPV) Associated Cancer Therapeutics under Development by Companies163
Human Papillomavirus (HPV) Associated Cancer Therapeutics under Investigation by Universities/Institutes191
Human Papillomavirus (HPV) Associated Cancer Pipeline Products Glance203
  Late Stage Products201
  Clinical Stage Products211
  Early Stage Products221
Human Papillomavirus (HPV) Associated Cancer Products under Development by Companies233
Human Papillomavirus (HPV) Associated Cancer Products under Investigation by Universities/Institutes261
Human Papillomavirus (HPV) Associated Cancer Companies Involved in Therapeutics Development2737
  Admedus Ltd271
  Advaxis, Inc.281
  Antigen Express, Inc.291
  Bionor Pharma ASA301
  BioNTech AG311
  Cancer Research Technology Limited321
  Cell Medica Limited331
  Etubics Corporation341
  EyeGene, Inc.351
  Formune S.L.361
  Genexine, Inc.371
  Genticel S.A.381
  iBio, Inc.391
  Immunovaccine, Inc.401
  Inovio Pharmaceuticals, Inc.411
  Inthera Bioscience AG421
  Johnson &Johnson431
  Karyopharm Therapeutics, Inc.441
  Kite Pharma, Inc.451
  MedImmune, LLC461
  Novartis AG471
  Onconova Therapeutics, Inc.481
  Oryx GmbH &Co. KG491
  Profectus BioSciences, Inc.501
  Selecta Biosciences, Inc.511
  Shantha Biotechnics Limited521
  Sirnaomics, Inc.531
  Theravectys SA541
  THEVAX Genetics Vaccine USA Inc551
  Tomegavax, Inc.561
  Transgene SA571
  UbiVac, LLC581
  Vaccibody AS591
  Vault Pharma Inc.601
  Virometix AG611
  ViroStatics srl621
  VLPbio631
Human Papillomavirus (HPV) Associated Cancer Therapeutics Assessment649
  Assessment by Monotherapy Products641
  Assessment by Target652
  Assessment by Mechanism of Action672
  Assessment by Route of Administration692
  Assessment by Molecule Type712
Drug Profiles7389
  ABI-1968 Drug Profile731
  AEH-10p Drug Profile741
  alpelisib Drug Profile753
  Antibodies to Target E6 for HPV Associated Cancer Drug Profile781
  Antibodies to Target E7 for HPV Associated Cancer Drug Profile791
  BVAC-C Drug Profile801
  Cellular Immunotherapy for HPV Associated Cancers Drug Profile811
  Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer Drug Profile822
  Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer Drug Profile842
  CerviVax Drug Profile861
  CMD-004 Drug Profile871
  DPV-001 Drug Profile882
  DPXE-7 Drug Profile901
  EDA-HPVE7 Drug Profile911
  EG-HPV Drug Profile921
  Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer Drug Profile931
  ETBX-041 Drug Profile941
  GTL-001 Drug Profile953
  GTL-002 Drug Profile981
  GX-188E Drug Profile992
  human papillomavirus (7-valent) vaccine Drug Profile1011
  human papillomavirus [Serotype 16] vaccine Drug Profile1021
  human papillomavirus [serotypes 16] vaccine Drug Profile1031
  human papillomavirus vaccine Drug Profile1041
  human papillomavirus vaccine Drug Profile1051
  human papillomavirus vaccine Drug Profile1061
  human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar Drug Profile1071
  INO-3106 Drug Profile1081
  INO-3112 Drug Profile1092
  Lm-LLO-ISG15 Drug Profile1112
  LN-145 Drug Profile1132
  Monoclonal Antibody to Target E6 and E7 Proteins for Oncology Drug Profile1151
  NIT-02 Drug Profile1161
  NP-001 Drug Profile1171
  PVX-01 Drug Profile1181
  Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers Drug Profile1191
  Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia Drug Profile1201
  rigosertib sodium Drug Profile12111
  sdCMV-002 Drug Profile1321
  SEL-701 Drug Profile1331
  Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers Drug Profile1341
  Small Molecules for Solid Tumors and HPV Associated Cancer Drug Profile1351
  STP-909 Drug Profile1361
  Subunit Vaccine for HPV Associated Cervical Cancer Drug Profile1371
  Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer Drug Profile1381
  TA-CIN Drug Profile1391
  TG-4001 Drug Profile1402
  TVGV-1 Drug Profile1421
  Vacc-HPV Drug Profile1431
  Vaccine for HIV and HPV Associated Cancer Drug Profile1441
  Vaccine for HPV Associated Cancer Drug Profile1451
  Vaccine for HPV Associated Cancers Drug Profile1461
  Vaccine for HPV Associated Cervical Cancer Drug Profile1471
  Vaccine for HPV Associated Cervical Cancer Drug Profile1481
  Vaccine for HPV Associated Cervical Cancer Drug Profile1491
  Vaccine for HPV Associated Skin Cancer Drug Profile1501
  Vaccine for Human papillomavirus Associated Cervical Cancer Drug Profile1511
  VB-1016 Drug Profile1522
  verdinexor Drug Profile1541
  VGX-3100 Drug Profile1553
  Vicoryx Drug Profile1581
  VMT-2 Drug Profile1591
  VPI-241 Drug Profile1601
  Vvax-001 Drug Profile1611
Human Papillomavirus (HPV) Associated Cancer Dormant Projects1622
Human Papillomavirus (HPV) Associated Cancer Product Development Milestones1647
  Featured News &Press Releases1641
    Jul 06, 2016: Genticel Appoints Eumedix as Strategic Advisor to Support Company S Access to Innovative Drug Candidates1641
    Jun 23, 2016: Genticel Reports 18 Month Interim Analysis of GTL001 Phase 2 Trial in HPV16/18 Infected Women1641
    Jun 15, 2016: Genticel to Present Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria1651
    Jun 01, 2016: Genticel Announces Publication in Clinical Cancer Research of Phase 1 Trial Results Supporting Safety, Tolerability and Immunogenicity of GTL0011651
    Apr 20, 2016: Genticel Reports Additional Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL0011661
    Oct 01, 2015: Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers1671
    Jun 01, 2015: Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, Its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform1681
    Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress1691
    Mar 05, 2014: Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza1691
    Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine1701
Appendix1712
  Methodology1711
  Coverage1711
  Secondary Research1711
  Primary Research1711
  Expert Panel Validation1711
  Contact Us1711
  Disclaimer1721

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016" Sep 14, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Human-Papillomavirus-HPV-Associated-Cancer-Pipeline-Review-H2-2016-2088-16545>
  
APA:
Global Markets Direct - Market Research. (2016). Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Human-Papillomavirus-HPV-Associated-Cancer-Pipeline-Review-H2-2016-2088-16545>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.